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Abstract
Background: Estrogen receptor α (ERα) phosphorylation is important for estrogen-dependent
transcription of ER-dependent genes, ligand-independent receptor activation and endocrine
therapy response in breast cancer. However ERα phosphorylation at the previously identified sites
does not fully account for these receptor functions. To determine if additional ERα
phosphorylation sites exist, COS-1 cells expressing human ERα were labeled with [32P]H3PO4 in
vivo and ERα tryptic phosphopeptides were isolated to identify phosphorylation sites.
Results: Previously uncharacterized phosphorylation sites at serines 46/47, 282, 294, and 559
were identified by manual Edman degradation and phosphoamino acid analysis and confirmed by
mutagenesis and phospho-specific antibodies. Antibodies detected phosphorylation of endogenous
ERα in MCF-7, MCF-7-LCC2, and Ishikawa cancer cell lines by immunoblot. Mutation of Ser-282
and Ser-559 to alanine (S282A, S559A) resulted in ligand independent activation of ERα as
determined by both ERE-driven reporter gene assays and endogenous pS2 gene expression in
transiently transfected HeLa cells. Mutation of Ser-46/47 or Ser-294 to alanine markedly reduced
estradiol dependent reporter activation. Additionally protein kinase CK2 was identified as a kinase
that phosphorylated ERα at S282 and S559 using motif analysis, in vitro kinase assays, and incubation
of cells with CK2 kinase inhibitor.
Conclusion: These novel ERα phosphorylation sites represent new means for modulation of ERα
activity. S559 represents the first phosphorylation site identified in the extreme C-terminus (F
domain) of a steroid receptor.
Background
ERα is a member of the nuclear receptor superfamily of
transcription factors whose activity is primarily regulated
by the binding of small lipophilic ligands. Estradiol-
induced ERα signaling is indispensable for many physio-
logical processes including reproductive tissue develop-
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ment (uterus, mammary gland, and ovary), bone
metabolism, and immune, cardiovascular, and neurolog-
ical function(1-3). Importantly, ERα has remained the
primary pharmacological target for endocrine therapy of
ERα positive breast cancer. Selective estrogen receptor
modulators (SERMs) such as tamoxifen, as well as estro-
gen ablation are front line therapies for the treatment of
ERα-expressing breast neoplasias.
Various aspects of ERα transcriptional activation are
dependent on phosphorylation of the receptor. Coactiva-
tor recruitment, subcellular localization, receptor dimeri-
zation, ligand binding, and posttranslational
modifications are regulated through the phosphorylation
of individual sites of ERα. Nine ERα phosphorylation sites
have been functionally characterized to date: serines 102
(S102), 104 (S104), 106 (S106), 118 (S118), and 167
(S167) in the AF-1 domain; serine 236 (S236) in the DNA
binding domain; and serines 305 (S305), threonine 311
(T311), and tyrosine 537 (Y537) in the AF-2/ligand bind-
ing domain (LBD) (Figure 1). The functional interaction
of ERα with coregulator proteins such as CBP/p300 and
the p160 family of coactivators is regulated by phosphor-
ylation of ERα in the AF-1 domain [1-4]. S118 is phos-
phorylated in response to both estradiol and epidermal
growth factor through CDK7 and ERK1/2 dependent
pathways, respectively [5,6]. Phosphorylation of S118 in
conjunction with S104 and S106 mediates ligand inde-
pendent activation of ERα by facilitating functional ERα
interactions with the transcriptional coactivators CBP and
SRC-1 [3]. It has also been demonstrated that glycogen
synthase kinase 3 (GSK-3) can mediate phosphorylation
of S102, S104, S106, and S118 in vivo and vitro, where
S102 phosphorylation is dependent on pS104 [7]. S167
of ERα is also phosphorylated in response to epidermal
growth factor receptor signaling through p90 RSK (p90
ribosomal S6 kinase), thereby significantly enhancing
ERα transcriptional activity [8]. This laboratory demon-
strated that src kinase dependent activation of AKT
resulted in phosphorylation of ERα at S167 and this site
was necessary for src mediated ERα transcriptional activity
[4]. Additionally, protein kinase CK2 which is upregu-
lated in most proliferating tissues, phosphorylates S167
and regulates interaction of ERα with estrogen response
elements (ERE) in vitro [9,10].
In addition to phosphorylation sites that have been func-
tionally characterized, recent studies have identified novel
phosphorylation events at sites S102, S154, S212, S294,
S554, and S559 by mass spectrophotometry [11,12]. Con-
current studies described herein have confirmed S294 and
S559 as bona fide ERα phosphorylation sites using phos-
pho-peptide mapping and have ascribed the initial func-
tional significance of these sites to ERα transcriptional
activity. Additionally, antibodies utilized within this
study have detected in vivo phosphorylation of S282,
S294, and S559 in immunohistochemical analysis of
human breast carcinoma tissue microarrays [13].
Estrogen receptor α (ERα) phosphorylation sites Figure 1
Estrogen receptor α (ERα) phosphorylation sites. The schematic in Figure 1 depicts both previously identified and novel 
ERα phosphorylation sites with relative locations within the ERα functional domains. Serines 104, 106, 118, and 167 constitute 
phosphorylation sites within the ligand-independent activation function-1 (AF-1) domain of ERα. S236 is the first phosphoryla-
tion site within the DNA binding domain of ERα. Serine 305, threonine 311 and tyrosine 537 are phosphorylation sites identi-
fied within the ligand-dependent activation function-2 (AF-2) domain. Indicated in bold italicized type are newly characterized 
phosphorylation sites of ERα: S46/47, S282, S294 and S559. S46/47 constitutes an additional site of phosphorylation within the 
AF-1 domain. Serines 282 and 294 are located in the hinge domain of ERα proximal to the DNA binding domain. Of note, S559 
is the first phosphorylation site identified in the extreme C-terminal F domain of ERα and other steroid receptors. S154, S212, 
S294, S554, and S559 have been recently identified or independently confirmed by mass spectrophotometry (11).
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Until recently, evidence for a role of ERα phosphorylation
in breast cancer had been extrapolated from breast cancer
cell line models. However, recent studies demonstrate
that ERα phosphorylation may significantly impact ERα
signaling in human tissues. Immunohistochemical stud-
ies have demonstrated S118 phosphorylation of ERα in
breast cancer patient biopsies [6,14]. S118 phosphoryla-
tion was associated with improved disease free survival
despite the ability of S118 phosphorylation to mediate
ligand independent ERα function and association of S118
phosphorylation with EGFR signaling, a known contribu-
tor to tamoxifen resistance in tissue culture models
[15,16]. Furthermore, S118 phosphorylation was directly
associated with tamoxifen sensitivity as well as with a
more highly differentiated tumor phenotype [17,18].
Another study, however, found that ERα S118 phosphor-
ylation was related to Her2 expression and tamoxifen
resistance upon patient relapse [19]. S167 phosphoryla-
tion has also been correlated to responsiveness to endo-
crine therapy as well as increased disease free and overall
survival in breast cancer patients [20]. Interestingly, S167
is downstream of AKT signaling which has been associ-
ated with tamoxifen resistance and agonist activity in
endometrial cancer cells [4]. Most recently, it has been
reported that low levels of S118 phosphorylation accom-
panied by high levels of S167 phosphorylation were asso-
ciated with increased overall survival and disease-free
survival in a study of breast cancer patient biopsies [21].
Furthermore it was recently suggested that phosphoryla-
tion of serine 305 in premenopausal women with breast
cancer was related to tamoxifen resistance [22]. Although
the number of clinical studies correlating ERα phosphor-
ylation and patient prognosis/outcome are relatively few,
these studies present the possibility that ERα phosphor-
ylation could be predictive of responsiveness to endocrine
therapy in ERα positive breast cancer.
A number of reports indicate that the most studied of the
previously identified ERα phosphorylation sites are not
the critical targets of signaling pathways that regulate the
relative antagonist or agonist properties of tamoxifen.
Three N-terminal serine phosphorylation sites (S104,
S106, S118) in ERα were shown to be necessary, but not
sufficient for growth factor potentiation of ligand-
dependent activation and ligand-independent activation
of the ERα [5,23-25]. Of significance from these studies
was the recognition that at least three otherERα serine
phosphorylation sites remained to be identified in vivo.
With the expectation that additional ERα phosphoryla-
tion sites may play a primary role in the modulation of
ERα function, the present study sought to identify novel
ERα phosphorylation sites employing in vivo labeling of
mammalian cells with [P32]H3PO4, phosphopeptide
mapping and biochemical identification of sites. The
present study has identified four novel ERα phosphoryla-
tion sites in vivo at serine residues S46/47, 282, 294, and
559. The identification and characterization of these
novel ERα phosphorylation sites will provide further
insight into ERα function in both normal and disease
states.
Results
Identification of serines 47, 282, 294, and 559 as novel ER  
phosphorylation sites
To identify hitherto unidentified ERα phosphorylation
sites, the present study employed the same approach used
by this laboratory to identify phosphorylation sites in
coactivator SRC-1 [26]. Briefly, COS-1 cells expressing
ERα were labeled in vivo, with [P32]H3PO4 and ERα was
immunopurified and fractionated by SDS-PAGE. A small
aliquot was used to confirm purification of ERα (Figure
2A). Following autoradiography of the wet gel, the 67Kd
band corresponding to ERα was excised, subjected to tryp-
tic digestion, and ERα tryptic peptides were separated on
a C-18 reverse-phase HPLC column using a 0-45% ace-
tonitrile gradient. Radiolabeled peptides were collected
and electrophoresed on a 40% alkaline acrylamide gel
and autoradiographed to reveal sites of P32 incorporation
corresponding to ERα phosphorylation (Figure 2B). Sub-
sequently, phosphopeptides were subjected to phos-
phoamino acid analysis and modified manual Edman
degradation to determine the position of each phos-
phoamino acid within the phosphopeptides. Data was
obtained for individual phosphopeptides isolated from
HPLC fractions or alkaline polyacrylamide gels contain-
ing each of the four major phosphopeptides labeled A-D
in Figure 2B. Phosphoamino acid analysis indicated that
each phosphopeptide contained only phospho-serine
(Figure 2C). Modified manual Edman degradation deter-
mined the position of P32phosphorylated amino acids
within each phosphopeptide as follows: phosphopeptide
A, P32 release at cycle 5; phosphopeptide B, P32release at
cycle 4; phosphopeptide C, P32 release at cycle 7, and;
phosphopeptide D, P32 release at cycle 10 (Figure 2D).
Comparison of these results to the predicted tryptic pep-
tides of ERα revealed a single candidate phosphopeptide
for phosphopeptide A and for phosphopeptide B (Table
1). The phosphorylation site in phosphopeptide A was
identified as serine 282 and the site in phosphopeptide B
was identified as serine 559. S559 phosphorylation has
been recently reported by Atsriku et al. through MALDI-
TOF mass spectrophotometry in ERα + MCF-7 cells,
thereby validating that S559 is a phosphorylation site for
ERα [11]. For phosphopeptide C there were four candi-
date peptides predicted to have a cycle 7 serine release by
manual Edman degradation (Table 1). S294 was a pre-
dicted substrate for Ser/Pro directed kinases and this
sequence is conserved among nuclear receptors (see Table
2). Two of the other three candidates for phosphopeptideBMC Biochemistry 2009, 10:36 http://www.biomedcentral.com/1471-2091/10/36
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C were not predicted to be phosphorylation sites accord-
ing to NetPhosK phosphorylation prediction models [27].
The fourth candidate, S527, was a predicted substrate for
PKC but the sequence is not conserved among nuclear
receptors. Therefore of the four candidate phosphopep-
tides, S294 was the most likely candidate for the phospho-
rylated residue contained within peptide C. As with S559,
S294 has recently been confirmed as a ERα phosphoryla-
tion site by MALDI-TOF mass spectrophotometry in MCF-
7 cells [11]. Similarly for phosphopeptide D, two possible
peptides were predicted to have a cycle 10 serine release
by manual Edman degradation; either S47 or S193. S47
was contained in an imperfect consensus sequence for
PKC whereas S193 was not within a predicted kinase rec-
ognition sequence (Table 1).
To distinguish among the candidate peptides for phos-
phopeptides C and D, and to provide further confirma-
Identification of ERα phosphorylated at serine residues 47, 282, 294 and 559 Figure 2
Identification of ERα phosphorylated at serine residues 47, 282, 294 and 559. 6 × 108 COS-1 cells were cultured in 
phenol red free DMEM supplemented with 10% charcoal stripped FBS. Cells were transfected with wt ERα expression plasmid 
as noted in materials and methods. 24 hours post-transfection, cells were phosphate-depleted and medium was exchanged 
with phosphate free DMEM supplemented with 1% dialyzed FBS. 4 mCi [P32] H3PO4 and 10-8 M estradiol were added to each 
plate and incubated overnight. Cells were subjected to denaturing lysis, ERα purified by immuno-affinity column, eluted, and 
fractionated by SDS-PAGE. (A) The band corresponding to the 67 kDa ERα was excised and subjected to tryptic digestion. 
Tryptic ERα peptides were separated by reverse phase HPLC using a C-18 column and 0-45% acetonitrile gradient over 90 
minutes. (B) Fractions were collected, pooled according to HPLC retention times and electrophoresed on 40% acrylamide 
alkaline peptide gels. Gels were autoradiographed, revealing distinct ERα phosphopeptides. 4 novel phosphopeptides (A, B, C, 
and D) resulting from tryptic digestion of ERα were identified. Each phosphopeptide was then excised, and subjected to modi-
fied manual Edman degradation (MED) and phosphoamino acid analysis as described in Materials and Methods. (C) Phos-
phoamino acid analysis revealed that the phosphopeptide A, B, C and D contained only phosphoserine. Representative 
phosphoamino acid analyses autoradiograms are presented with identical results detected for phosphopeptides A, B, C, and D. 
(D) MED detected 32P release for phosphopeptides A-D. Combined data for phosphoamino acid analysis and MED is pre-
sented in Table 1.
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tion of the identity of all phosphorylation sites in
phosphopeptides A-D, serine to alanine mutant ERα
expression constructs were generated at sites S47, S282,
S294, and S559 (S47A, S282A, S294A, S559A). ERα
mutants were expressed in COS-1 cells and
P32phosphopeptide maps were prepared and compared
to phosphopeptide maps of wild-type (wt) ERα (Figure
3A-E). Phosphopeptide maps of S294A or S559A resulted
in specific loss of phosphopeptides C and B, respectively
(Figure 3B-C). The phosphopeptide map of S47A resulted
in reduced intensity but not complete loss of phos-
phopeptide D (Figure 3D). A close examination of the first
tryptic cleavage site directly C-terminal to S47 revealed a
lysine-proline sequence at residues 48-49. Trypsin cleaves
inefficiently at R/K-proline sequences making it possible
that phosphopeptide D was the result of an incomplete
tryptic digest [28]. The next trypsin cleavage site following
an incomplete digest at K48 occurs at residue R142 and
digestion at this site would result in a very large phos-
phopeptide of 110 amino acids. The possibility of an
incomplete tryptic digest at K48 was consistent with the
relative migration of phosphopeptide D at the top of the
alkaline acrylamide gel, and the elution of this phos-
phopeptide in the later fractions from the C18 reversed
phase column (25). Since the previously identified ERα
phosphorylation sites S104, S106, and S118 would also
be present in the very large phosphopeptide resulting
from incomplete digestion of K48, an ERα expression
plasmid was constructed containing four serine-to-
alanine mutations at S47, S104, S106, and S118 and a
phosphopeptide map of this protein was prepared. As
shown in Figure 3E, S47A/S104A/S106A/S118A resulted
in complete loss of phosphopeptide D consistent with the
interpretation that all four phosphorylation sites S47,
S104, S106, and S118 were present in phosphopeptide D.
Additionally, it was noted that phosphopeptide C was
diminished upon mutation of S104, S106, S47 and S118,
suggesting that S294 phosphorylation, or a site within a
peptide which co-migrates electrophoretically with pep-
tide C may be dependent upon phosphorylation of one or
several sites within the D peptide (Figure 3D and 3E).
Despite multiple attempts, phosphopeptide maps of
S282A consistently resulted in a very weak steady state
ERα phosphorylation profile. This was likely the result of
estradiol induced loss of S282A protein after 24 hours
(Figure 3F). This effect was time dependent since estradiol
did not reduce S282A protein after 3 hours incubation.
The destabilization of ERα by mutation of S282A is cur-
rently under investigation. The effect of phosphorylation
site mutation on phosphorylation at other sites is also
under investigation.
Phospho-specific antibodies recognize ERα 
phosphorylated at serines 282, 294, and 559
To further verify the authenticity of the phosphorylation
sites identified by the biochemical approaches above and
to study the impact of ERα phosphorylation at S47, S282,
Table 1: Identification of novel ERα phosphorylation sites.
Peptide Amino acid MED Cycle Candidate phosphopeptides Identity Verified by mutagenesis Phospho- antibody
AS e r i n e 5 278-GEVG (S) AGDMR-287 Serine 282 + +
BS e r i n e 4 556-GGA (S) 
VEETDQSHLATAGSTSSHSLQK-581
Serine 559 + +
CS e r i n e 7 172-GSMAME (S) AK-180
288-AANLWP (S) PLMIK-299
450-SIILLN(S)GVYTFLSSTLK-467
521-GMEHLY(S)MK-529
Serine 294 + +
DS e r i n e 1 0 38-PLGEVYLDS (S) 
KPAVYNYPEGAAYEFNAAAA
ANAQVYGQTGLPYGPGSEAAAFGSNGL
GGFPPLNSV(S)P(S)PLMLLHPPPQL (S) 
PFLQPHGQQVPYYLENE
PSGYTVR-142
184-YCAVCNDY (S) 
GYHYGVWSCEGCK-206
Serine 47 + -
Table 2: Consensus kinase recognition sequences for novel ERα phosphorylation sites
Phosphorylation site Sequence Consensus recognition site Putative Kinase
Serine 47 YLD-(S)-(S)K-PAV (S/T)-X-R/K PKC? (imperfect)
Serine 282 GEVG-(S)AGD-M (S/T)-X-X-E/D CK2
Serine 294 NLWP-(S)P-LMI (S/T)-P Proline-directed kinase
Serine 559 RGGA-(S)VEE-T (S/T)-X-X-E/D CK2BMC Biochemistry 2009, 10:36 http://www.biomedcentral.com/1471-2091/10/36
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S294, and S559, phospho-specific antibodies to each site
were generated. Immunogens (phosphorylated peptides)
were designed and rabbit polyclonal antibodies were gen-
erated against each phosphorylation site as previously
described by this laboratory [29]. To validate the phos-
pho-specific antibodies, S47A, S282A, S294A or S559A
were expressed in COS-1 cells and lysates were subjected
to Western immunoblotting with total ERα antibody and
with phospho-specific antibodies to each site (Figure 4A).
Each point mutation was expressed at comparable levels
to wt ERα. Each phospho-specific antibody recognized wt
ERα but the phospho-specific antibodies to sites S282,
S294 and S559 did not recognize the corresponding
mutations S282A, S294A, and S559A confirming that
phosphorylation at these sites was necessary for the
immuno-reactivity. In contrast, mutation S47A was still
recognized by the phospho-antibody to pS47. Of interest
was the decreased electrophoretic mobility of ERα upon
mutation of S47 to alanine (Figure 5C). This reduced
mobility may be indicative of further post-translational
modifications that are regulated by S47 phosphorylation
similar to what has been observed for S305A mutations
(27).
Mutation of serine residues to alanine eliminates specific phosphorylation of peptides Figure 3
Mutation of serine residues to alanine eliminates specific phosphorylation of peptides. To confirm the identity of 
phosphorylated serine residues within peptides A, B, C, and D, serine to alanine mutations were introduced into wt ERα 
(S47A, S282A, S294A, or S559A). 12 plates of COS-1 cells (4 × 107 /plate) were transfected with 500 ng/plate of wt ERα, S47A, 
S282A, S294A, or S559A expression plasmids. 18 hours post-transfection, cells were phosphate-depleted, labeled with 4 mCi 
[32P]H3PO4 and incubated with 10-8 M estradiol overnight. ERα was immunopurified and tryptic peptides were separated by 
HPLC using a C-18 reversed phase column. Fractions were collected and electrophoresed on a 40% alkaline polyacrylamide gel 
followed by autoradiography. (A) Peptide map of wt ERα displaying 4 novel phosphopeptides A-D. (B) S294A resulted in loss 
of peptide C. C) S559A resulted in loss of peptide B. (D) S47A resulted in a modest decrease in peptide D compared to wt 
ERα. E) S47A/S104A/S106A/S118A resulted in loss of peptide D. (F) Mutation of S282 to alanine reduces ERα protein 
following 24 h incubation with estradiol. 106 COS-1 monkey embryonic kidney cells which had been cultured in phenol-
red free DMEM supplemented with 10% fetal bovine serum were transfected with 2.5 μg of wt ERα or S282A expression plas-
mid. 24 hours after transfection, cells were incubated with vehicle (veh) or estradiol (10-8M) for an additional 24 hours. Cell 
lysates were collected and ERα protein levels determined, using α-tubulin as a loading control.
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To further validate the specificity of the ERα phospho-spe-
cific antibodies, baculovirus expressed recombinant ERα
was incubated with and without λ-phosphatase followed
by Western blotting with phospho-specific antibodies.
Each antibody was determined to be phosphorylation
state specific as evidenced by the lack of immunoreactivity
following incubation with λ-phosphatase (Figure 4B).
The results for α-pS47 were inconclusive since mutation
of this residue failed to inhibit immunoreactivity, yet
dephosphorylation by λ phosphatase indeed decreased
immunoreactivity (data not shown). These findings lend
evidence to the existence of an alternative phosphoryla-
tion site within the region corresponding to the immuno-
genic peptide used to generate the pS47 antibody. It was
therefore investigated whether phosphorylation of the
adjacent serine 46 (S46) was responsible for the immuno-
reactivity of the α-p-S47 antibody. Results indicate that
mutation to alanine of either S46, S47 or S46/S47 did not
block immunoreactivity of the p-S47 antibody to ERα
(data not shown) indicating that the α-p-S47 antibody
was not specific for the Western blotting procedure. As
such, the α-pS47 antibody was not used for subsequent
studies. It is possible this antibody may demonstrate spe-
cificity in other procedures (e.g. IHC) and this is currently
being investigated.
Endogenously expressed ERα is phosphorylated at S282, 
S294, and S559
To determine whether endogenously expressed ERα was
phosphorylated at sites S282, S294, and S559, ERα was
first immunoprecipitated using phosphospecific antibod-
ies directed towards p-S282, p-S294, and p-S559, fol-
lowed by Western blotting with antibody to total ERα in a
panel of ERα+ breast cancer cell lines. Using this
approach, phosphorylation at each site was detected in
MCF-7 breast cancer cells and MCF-7-LCC2 cells, a
tamoxifen resistant derivative of MCF-7 [30]. ERα+
Ishikawa endometrial adenocarcinoma cells did not
exhibit substantial phosphorylation at S559, and weak
immunoreactivity for S294 and S282 phosphorylation
observed. These studies indicate that ERα is phosphor-
ylated at serines S282, S294, and S559 in endogenous ERα
expressing breast and endometrial cancer cells. It should
be noted that phosphospecific antibodies for p-S282, p-
S294, and p-S559 also detected phosphorylated ERα in
ERα positive human breast carcinomas [13].
To determine if the phosphorylation of ER at S282, S294,
or S559 was regulated by estradiol, MCF7 cells were incu-
bated for 30 minutes with 10-8 M estradiol. Estradiol
markedly increased phosphorylation at sites S282 and
S559 but had little effect on S294 (Figure 6B). These data
Confirmation of the specificity of ER phospho-antibodies Figure 4
Confirmation of the specificity of ER phospho-antibodies. (A) Serine to alanine mutations at ERα phosphorylation sites 
inhibit reactivity of phospho-specific antibodies. COS-1 cells cultured in DMEM growth supplemented with 10% FBS were tran-
siently transfected with 500 ng of either wt ERα or serine to alanine substituted ERα expression plasmids (S47A, S282A, 
S294A, or S559A). 18 hours post-transfection, cells were lysed and subjected to Western immunoblot analysis utilizing custom 
polyclonal antibodies directed toward the individual phosphorylated ERα residues (S47, S282, S294, or S559) or monoclonal 
ERα antibody as indicated. α-p-S282, α-p-S294, or α-p-S559 antibodies did not recognize S282A, S294A, or S559A, respec-
tively, indicating phospho-antibody specificity. Mutation of S47 failed to eliminate immunoreactivity of αp-S47. (B) In vitro λ 
phosphatase treatment of ERα inhibits immunoreactivity of ERα phospho-antibodies. Baculovirus expressed ERα was sub-
jected to dephosphorylation by λ phosphatase for 30 minutes at 30°C and analyzed by Western immunoblot with antibodies 
against p-S282, p-S294, p-S559, and total ERα. Dephosphorylation inhibited immunoreactivity of, α-p-S282, α-p-S294, and α-p-
S559 without impacting immunoreactivity of total ERα antibody.
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further demonstrate that phosphorylation of ERα at S282,
S294 and S559 comprise an integral component of endog-
enous ERα signaling.
ERα phosphorylation at novel sites impacts ERα regulated 
gene expression
To determine the role of ERα phosphorylation in receptor
mediated transcription, ERα negative [ERα(-)] HeLa cervi-
cal cancer cells were cotransfected with individual ERα
phospho mutant expression plasmids and a reporter plas-
mid (ERE2-TK-luciferase) containing two canonical ERE
sequences. Mutation of a serine residue to non-phospho-
rylatable alanine mimics loss of a phosphorylation site.
S282A and S559A exhibited a significant increase in basal
reporter activity compared to wt ERα but these mutants
exhibited no statistical difference compared to wt ERα in
estradiol-dependent reporter activation (Figure 5A).
S294A exhibited reduced estradiol-dependent reporter
activation. S47A mutants showed a trend toward
increased basal and ligand dependent activation in
reporter assays, but did not reach statistical significance.
These data suggest that phosphorylation at sites S282 and
S559 inhibit ligand-independent activation of ERα, and
that phosphorylation at S294 is required for full estradiol
activation of gene transcription.
Real time RT-PCR was used to measure expression of the
endogenous estrogen responsive gene pS2 in HeLa cells
transiently transfected with wt ERα or mutant ERα expres-
sion plasmids. The pS2 promoter contains separate ERE
and AP-1 sites [31,32]. Most intriguing and consistent
with the reporter gene results in Figure 5A, expression of
S559A resulted in significantly elevated ligand independ-
ent activation of pS2 (Figure 5B). Similarly, S282A also
resulted in elevated ligand independent activation of pS2.
S47A exhibited significant repression of estradiol-induced
pS2 expression, which was in contrast to what was
observed with the reporter gene assay. S294A exhibited no
change in either basal or estradiol induced pS2 expression
compared to wt ERα. The differential effects observed with
regard to S47A and S294A regulation of pS2 versus the
ERE2-TK-luciferase reporter gene likely reflect gene specific
effects for ERα phosphorylation. Interestingly, the ERE of
the pS2 gene works in synergy with an adjacent AP-1 site
to mediate estradiol induced pS2 expression [31,33]. Fig-
ure 5C demonstrates that an equivalent level of ERα pro-
tein was detected for wt ERα and the mutants.
One limitation of ERα(-) cells such as HeLa to study pS2
or other endogenous gene expression, is that these cells do
not express pS2 and cells transiently transfected with ERα
expression plasmids likely produce low levels of pS2 pro-
tein following estradiol treatment due to limitations of
the transient transfection approach. Future studies will
directly mutate ERα phosphorylation sites of the endog-
enous ESR-1 gene in cells that robustly express ERα to
overcome the limitations of transient transfection
employed here.
Although biochemical identification and site directed
mutagenesis identified S47 as a novel phosphorylation
site in phosphopeptide D, the α-pS47 phosphospecific
antibody retained immunoreactivity with S47A. Since λ
phosphatase resulted in loss of immunoreactivity of α-
pS47 antibody the possibility was raised that the adjacent
serine, S46, might be phosphorylated in the S47A mutant.
NetPhosK software revealed that S46 forms a putative rec-
ognition sequence for protein kinase C classic isoforms
Phosphorylation of endogenous ERα in ERα (+) cell lines at S282, S294, and S559 Figure 5
Phosphorylation of endogenous ERα in ERα (+) cell lines at S282, S294, and S559. (A) 107 MCF-7 and MCF-7-
(LCC2) breast cancer and Ishikawa endometrial adenocarcinoma cell lines were cultured in medium supplemented with 10% 
FBS. Cells were lysed and total ERα was immunoprecipitated with α-p-S282, α-p-S294, or α-p-S559 antibodies for 3 hours. 
Immunoprecipitates were analyzed by Western blot for total ERα (B) S282 and S559 are phosphorylated following incubation 
of MCF-7 breast cancer cells with estradiol. MCF-7 breast cancer cells were cultured for 48 hours in phenol red free medium 
supplemented with 10% charcoal-stripped FBS. Cells were serum starved overnight prior to incubation with vehicle (veh) or 
10-8M estradiol (E2). ERα was immunoprecipitated from lysates and Western blot analysis performed with α-pS282, α-pS294, 
or α-pS559, and with α-ERα. Substantial ligand-induced phosphorylation was detected at S282 and S559, with only modest lig-
and induced phosphorylation at S294.
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that more closely resembles a canonical recognition motif
for PKC classical isoforms than does S47. To investigate
the possibility that S46 phosphorylation could be an
alternative phosphorylation site for S47 of ERα, serine to
alanine mutations were introduced at S46 and/or S47
(S46A, S46/S47A). ERα(-) HeLa cervical cancer cells were
cotransfected with S46A, S47A, or S46/47A expression
plasmids and ERE2-TK-luciferase reporter plasmid. Results
indicated that mutation of S46, but not S47, significantly
suppressed ERα transcriptional function (Figure 7A). The
46/47A mutant displayed similar activity to S46A, sug-
gesting that the predominant effect on transcriptional
activity was through S46 phosphorylation.
Protein kinase CK2 phosphorylates ERα S282 and S559 in 
vitro and in vivo
Motif analysis revealed that each phosphorylation site was
contained within known kinase recognition motifs (Table
2). S46/47 was present within an imperfect recognition
motif for classical PKC isoforms (S/T-X-K/R). S282 and
S559 were present within a consensus sequence for pro-
tein kinase CK2 phosphorylation (S/T-X-X-E). S294 was
present within a putative recognition motif for Ser/Pro
directed kinases. In vitro phosphorylation of baculovirus
expressed human ERα was performed with ERK1/2 (to
assess S294 phosphorylation), and protein kinase CK2α
catalytic subunit (to assess S282 and S559 phosphoryla-
tion) followed by Western blotting with phospho-specific
antibodies.  In vitro kinase assays with ERK1/2 did not
result in phosphorylation at S294 (data not shown). Incu-
bation of ERα with protein kinase CK2 resulted in phos-
phorylation of S282 and S559 in vitro (Figure 8A). These
findings are of significant interest with regard to CK2 over-
expression documented in various cancers, including
breast cancer [34].
Phosphorylation of ERα impacts receptor transcriptional activity Figure 6
Phosphorylation of ERα impacts receptor transcriptional activity. (A) ERα (-) HeLa cells were cotransfected with 
100 ng ERE2-TK-luciferase reporter and 200 ng wt ERα (wt), or serine to alanine mutants of ERα for each novel phosphoryla-
tion site (S47A, S282A, S294A, and S559A). 24 hours post transfection, cells were incubated with vehicle (veh) or estradiol (10-
8 M) overnight. Luciferase assays were performed and transcriptional activity was normalized to protein concentration and/or 
ERα expression by Western blot analysis. S47A exhibited similar transcriptional activity to wt ERα, whereas S294A resulted in 
suppressed transcriptional activity vehicle and estradiol. S282A and S559A displayed enhanced ligand independent transcrip-
tional activity as compared to wt ERα. (B) HeLa cervical cancer cells were transfected with 500 ng of wt ERα or ERα phos-
pho-mutant (S47A, S282A, S294A, S559A) expression plasmids. 24 hours post-transfection, cells were incubated with vehicle 
(veh), 10-8 estradiol (E2), for 3 hours. pS2 expression was measured by real-time RT-PCR, relative to GAPDH. S47A resulted 
in suppression of estradiol-induced pS2 expression, whereas S559A exhibited ligand-independent activation of ER. S282A and 
S294A displayed no statistical differences in pS2 mRNA. (C) HeLa cells were transfected with 500 ng of wt ERα or ERα phos-
pho-mutant (S47A, S282A, S294A, and S559A) expression plasmids and incubated for 3 hours with estradiol (1-8M) at 18-24 
hours post transfection. Transfection and incubation with estradiol were performed in parallel with those for RT-PCR (panel 
B). A and B represent composite results for 6 identical experiments. Statistical significance was determined using ANOVA and 
Fisher's LSD post-hoc analysis, p ≤ 0.05.
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To demonstrate the involvement of CK2 in the phospho-
rylation of ERα at S282 and S559 in vivo, MCF7 cells were
incubated with the highly selective CK2 inhibitor, DMAT
(2-dimethylamino-4,5,6,7- tetrabromo-1H-benzimida-
zole) for 1 hour, prior to incubation with E2 for 30 min-
utes. Cell lysates were subjected to immunoprecipitation
with α-pS282 and α-pS559 antibodies, and subsequently
Western blots using antibody to total ERα protein. DMAT
suppressed phosphorylation of S282 and S559 further
indicating that CK2 is responsible for the phosphoryla-
tion of both S282 and S559 of ERα (Figure 8B).
Discussion
The present study has characterized four novel phosphor-
ylation sites in human ERα in vivo. Two of these sites, S294
and S559, have been independently confirmed by mass
spectrophotometry in MCF-7 cells [11]. Additionally, col-
laborators at the University of Manitoba recently found
that ERα is phosphorylated at S282, S294, and S559 in
human breast carcinoma biopsies, lending evidence to the
physiological relevance of these sites in the breast cancer
[13]. S559 phosphorylation is the first phosphorylation
site identified in the extreme C-terminal (F domain) of a
steroid nuclear receptor [35]. Generation of phospho-spe-
cific ERα antibodies provided the tools to validate phos-
phorylation sites and to begin to assess the functional
significance of these specific sites. Accordingly, these
phospho-specific antibodies were used to detect phospho-
rylation of each residue by Western blot/immunoprecipi-
tation from cells that expressed endogenous ERα (Figure
6A and 6B). Phosphorylation at S46/47, S282, S294 and
S559 each had an impact on ERα mediated activation of
reporter gene ERE2-TK-luciferase and/or endogenous pS2
gene expression (Figure 5A and 5B). Two of these sites,
S282 and S559, were contained within consensus
sequences for protein kinase CK2 and were phosphor-
ylated by CK2 in vitro and in vivo (Figure 7, 8). In particu-
lar, phosphorylation changes at the F domain S559 site
had profound effects on ligand independent activation of
ERα. These findings provide valuable insight into the reg-
ulation of ligand dependent and ligand independent ERα
function. Furthermore, pharmacological targeting of the
cell signaling pathways that regulate ERα phosphoryla-
tion at these sites may represent therapeutic targets for
modulating ERα function.
S559, located in the F-domain of ERα, represents a very
intriguing phosphorylation site because mutation to
alanine enhances ligand independent activation of ERα
(Figure 5A and 5B). Studies have demonstrated that the F-
domain of various nuclear receptors may be responsible
for interaction with coregulators, and for determining the
relative agonist/antagonist character of several ERα lig-
ands [36]. At least two groups have demonstrated that F-
domain deletions, that included deletion of a regions con-
taining S559, enhanced transcriptional activity of ERα
[37,38]. Furthermore, SRC-1 association with ERα was
increased upon deletion of the F domain [39]. Another
report demonstrated that the intact ERα F-domain inhib-
ited the association of unliganded ER with REA (Repressor
of Estrogen Receptor) using in vitro GST pull down assays
[40]. These studies indicate that the F-domain of ERα was
responsible for the inhibition of ERα association with
both coactivators (SRC-1) and corepressors (REA).
Although these findings do not directly implicate a central
role for S559 phosphorylation in coregulator recruitment,
it does highlight the importance of the F-domain in ERα/
coregulator interactions. Interestingly, another report sug-
gested that point mutations of S559 and E562 to alanine
disrupted a predicted helix in the F-domain that resulted
in a slight inhibition of ligand independent transcrip-
tional activity and an enhanced estradiol-activation of
ERα mediated gene expression [38].
The phosphorylation of S282 and S294 may also be
important for regulating ERα function. The location of
S282 and S294 in the hinge region near the DBD is sug-
gestive of a role for these phosphorylation sites in DNA
binding and/or dimerization of ERα. The present data,
however suggest that phosphorylation of these residues
lead to opposing effects on ERα mediated transcription
(Figure 5A and 5B). Reporter gene data suggest that phos-
phorylation at S282, much like S559, was involved in the
suppression of unliganded ERα activity. However, muta-
tion of S282 also resulted in increased estradiol-depend-
ent loss of ER protein. As such, the impact of S282
phosphorylation may be biphasic. In the transient setting,
S282 phosphorylation may result in attenuated transcrip-
tional activity but may lend to long term stabilization of
ER protein levels allowing transcriptional activity to per-
sist over time. S294 mutation to alanine resulted in a sup-
pressive effect in reporter assays but not in expression of
the endogenous estrogen regulated gene pS2. One likely
explanation is that the complexity of the endogenous pS2
promoter allows other transcription factors/transcrip-
tional regulators to compensate for loss of ERα function
caused by mutation of S294 to alanine. The pS2 promoter
does indeed contain an AP-1 site that is thought to act in
concert with the ERE to mediate transcriptional activity. In
this setting, slight changes in ERE mediated transcrip-
tional function may be compensated with the AP-1 site.
S46/47 phosphorylation may play a role in the ligand
dependent activation of ERα. Data suggested that S46,
and not S47, is responsible for regulating ERα transcrip-
tional activity. S47 which was identified by biochemical
means, may be phosphorylated due to a "bystander effect"
in which kinases, (presumably PKC isoforms) are directed
to the S46 site but may phosphorylate both the S46 and
the weaker recognition site, S47. Alternatively, S46 andBMC Biochemistry 2009, 10:36 http://www.biomedcentral.com/1471-2091/10/36
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S47 phosphorylation events could be distinct events.
Indeed, S46 lies within an imperfect protein kinase C rec-
ognition motif as does S47 and mutation of S46 results in
substantial inhibition of ERE-luciferase activity in HeLa
cells but was not identified biochemically as an ERα phos-
phorylation site. Interestingly, mutation of S46 or S46/47
does not lead to the electrophoretic up shift observed
upon mutation of S47 alone suggesting that these sites
play distinct roles in ER transcriptional regulation. These
data can only be suggestive of S46 phosphorylation as
there has been no direct biochemical evidence that S46 is
phosphorylated. As with the other four A/B region phos-
phorylation sites (S104, S106, S118, S167), S47 may con-
tribute to the ligand independent and ligand dependent
function of the receptor. In agreement with this assertion
it has been demonstrated that murine ERα transcriptional
activity is induced by PKCδ through the AF-1 domain and
that PKCδ activity leads to phosphorylation of mouse ERα
[41]. Nonspecificity of the α-pS47 antibody precluded
further experiments that would have been necessary to
determine if PKC is indeed necessary for the phosphoryla-
tion of S46/47 and if this mediates the transcriptional
induction of ERα through the PKC pathway.
The finding that S282 and S559 were phosphorylated in
vivo and in vitro by protein kinase CK2 indicates a central
role for CK2 in the regulation of ERα transcriptional activ-
ity (Figure 7). Previous studies indicate that CK2 enhances
ERα DNA binding in vitro and that CK2 phosphorylates
ERα at serine 167 [9,10,42]. Previous work from this lab-
oratory demonstrated that mutation of S167 to alanine
markedly reduced ERα transcriptional activity and dis-
rupted ERα interaction with endogenous promoters [4].
S282 and S559 represent the second and third sites of ERα
regulation by CK2. Remarkably, mutation of S282 or
S559 to alanine resulted in near opposite functional
effects on ERα as compared to mutation of S167 to
alanine. ERα ligand independent transcriptional activity
was markedly enhanced upon mutation of S282 and S559
to alanine whereas estradiol mediated activation
remained equivalent to wt ERα (Figure 5A and 5B). These
findings suggested that CK2 phosphorylation maintains
ERα in a state in which basal ligand independent activity
is suppressed while responsiveness to ligand is retained.
This is significant in that CK2 overexpression has been
observed in several cancers including breast cancer
[34,43]. It has also recently been demonstrated that sev-
eral tamoxifen resistant breast cancer cell lines showed
greater susceptibility to apoptosis upon inhibition of CK2
compared to tamoxifen sensitive MCF-7 cells [44]. Addi-
tionally, developmental mouse models reveal a causative
role for CK2 in breast cancer in which MMTV-CK2α trans-
genic mice form mammary tumors at a frequency of 35%
as compared to > 1% in wt FVB mice [43]. Therefore, the
signaling axis of ERα and CK2 in breast cancer is of great
interest and provides a putative target for therapeutic
intervention.
The signaling axis between CK2 activity and ERα tran-
scriptional regulation has yet to be elucidated. Though
mutagenesis of sites demonstrated that absence of a phos-
phorylation event at S282 and S559 positively regulated
Mutation of S46 and S46/47 impacts receptor transcriptional  activity Figure 7
Mutation of S46 and S46/47 impacts receptor tran-
scriptional activity. (A) 105 ERα (-) HeLa cells were 
cotransfected with 100 ng ERE2-TK-luciferase reporter and 
200 ng wt ERα (wt), or serine to alanine mutants of ERα for 
S46 (S46A), S47A (S47A), or both S46 and S47 (S46/47A). 24 
hours post transfection, cells were incubated with vehicle 
(veh) or estradiol (10-8 M) for 18-24 hours. Luciferase assays 
were performed to determine the relative transcriptional 
activity of ERα and ERα phospho-mutants. Transcriptional 
activity was normalized to protein concentration and ERα 
expression by Western blot analysis. These studies demon-
strate that S46A and S46/47A lead to substantial inhibition of 
ERα mediated gene expression, whereas the activity of S47A 
remains similar to that of wt ERα. (B) Western blot analysis 
demonstrating expression of wt ERα, S46A, S47A, and S46/
47A. 105 HeLa cells were transfected with 500 ng of wt ERα 
or ERα phospho-mutant (S46A, S47A, or S46/47A) expres-
sion plasmids and incubated for 5 hours with estradiol (1-8M) 
at 18-24 hours post transfection. S47A shows an electro-
phoretic upshift not evident with wt ERα, S46A, or S46/47A. 
Panel A represents the composite of 3 experiments. Statisti-
cal significance was determined using ANOVA and Fisher's 
LSD post-hoc analysis, p ≤ 0.05.
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ER transcriptional activity, inhibition of CK2 by DMAT
inhibited ER transcriptional activity (data not shown).
One possibility to explain these findings is that CK2 may
be necessary for the activity of transcriptional coregulators
involved in ER signaling. A second explanation may be
that ER is phosphorylated by CK2 at additional sites (e.g.
S167).
Sequence alignment analysis (Megalign™, DNA*Star) was
used to determine conservation of phosphorylation at
S47, S282, S294, and S559 among other nuclear recep-
tors. S47, which lies in the highly heterologous and heav-
ily phosphorylated AF-1 region of ERα, was difficult to
align with AF-1 regions of other nuclear receptors and
consequently it was difficult to assess conservation of this
site among receptors. However because there is more
homology within the DBD, hinge and LBD regions of
nuclear receptors, phosphorylation at sites equivalent to
S282, S294 and S559 may be more highly conserved
among nuclear receptors. The hAR (human androgen
receptor) is phosphorylated by stress kinases (ie. Jun N-
terminal Kinase, p38 MAP kinase) within the hAR hinge
region (S650), a site that is homologous to and aligns
closely with S282 of ERα [45]. Interestingly, the (S)PTEE
sequence encompassing S650 comprises a putative CK2
recognition motif as does S282, suggesting some conser-
vation in phosphorylation between ERα and hAR. Func-
tionally, S650 phosphorylation of the hAR is suggested to
regulate nuclear export [46]. The hPR-B (human proges-
terone receptor B) is phosphorylated in the hinge region
by CDK2 at S676 [47]. However S676 phosphorylation
has not been ascribed mechanistic relevance in hPR-B
function and this site does not align closely with ERα
S282 or hAR S650 in alignment analysis. It is possible
however, that phosphorylation of hPR-B at S676 is
homologous to ERα S294. S294 is likely targeted by Ser-
ine-Proline (Ser-Pro) directed kinases and is located
within the hinge domain of ERα. Regarding S559 phos-
phorylation, to date no phosphorylation site has been
identified in the F domain of steroid receptors [35].
Motif analysis identified kinase recognition sequences in
other nuclear receptors that may be analogous to CK2
phosphorylation of S282 and S559. ERβ has putative CK2
recognition sites at S234 (SADE) and S513 (SPAE). S225
of RXRα (retinoid × receptor alpha) is contained within a
putative CK2 site (SANE) that aligns with, and may be
homologous to, S282 of ERα. The relatively high number
of putative CK2 phosphorylation sites within nuclear
receptors may indicate that CK2 phosphorylation is
intrinsically linked to cell cycle progression given that
CK2 expression and activity is increased in highly prolifer-
ating tissues [48].
These studies represent the first characterization of four
newly identified phosphorylation sites within ERα. One
caveat to these findings is the use of ERα (-) HeLa cells to
determine the impact of each phosphorylation site on
ERα transcriptional activity. HeLa cells only weakly sup-
port AF-1 activity of ERα. As such, these studies may rep-
resent mechanisms that are primarily representative of AF-
2 regulation. Indeed, three of the four identified phospho-
rylation sites lie outside of the AF1 domain suggesting that
these sites may function independently of AF-1. However
this does not preclude phosphorylation dependent inter-
action between AF-1 and AF-2 domains. Despite these
limitations, Hela cells support ERα transcriptional activity
in luciferase reporters and demonstrate the regulation of
endogenous estradiol regulated genes. Additionally,
because the cells are ERα (-), the influence of endogenous
ERα expression on estradiol-mediated gene transcription
is not present.
Conclusion
The study presented herein describes the initial identifica-
tion and/or functional characterization of S46/47, S282,
S294, and S559 as phosphorylation sites within ERα.
These studies show that phosphorylation at S46/47 or at
Protein Kinase CK2 phosphorylates of S282 and S559 Figure 8
Protein Kinase CK2 phosphorylates of S282 and 
S559. (A) 400 ng baculovirus expressed ERα was incubated 
in CK2 kinase buffer supplemented with 10 mM ATP, in the 
presence or absence of 200 ng recombinant catalytic α subu-
nit of CK2. Reactions were stopped with Laemmli buffer, 
subjected to Western blot analysis, and probed with α-
pS282, α-pS559, α-pS118 or αER. These studies show that 
the CK2α catalytic subunit specifically phosphorylates ERα at 
S282 and S559. Western blot for phosphorylation of S118, a 
site that exhibits strong phosphorylation in baculovirus 
expressed ERα, is shown for comparison to demonstrate 
absence of nonspecific phosphorylation by CK2 on other 
ERα phosphorylation sites. (B) 106 MCF7 breast cancer cells 
were pretreated with DMAT (4 uM) for 90 minutes, fol-
lowed by 30 minutes with estradiol (10-8 M) or vehicle. 
Immunoprecipitation of S282 or S559 was performed using 
phosphoantibodies and Western blot for total ERα. DMAT 
inhibited phosphorylation at both sites, indicating that CK2 
phosphorylates these sites in vivo.
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S294 likely potentiate ERα transcriptional activity
whereas S282 and S559 phosphorylation are likely to neg-
atively regulate ERα transcriptional activity as evidence by
mutational analysis. Additionally, this study identified
protein kinase CK2 as the kinase responsible for the phos-
phorylation of ERα at S282 and S559. The identification
and characterization of phosphorylation at S46/47, S282,
S294, and S559 provides additional insight into regula-
tion of ERα signaling. Ultimately, the impact of ERα phos-
phorylation at these sites will provide new diagnostic
tools in breast cancer and may lead to novel therapeutic
strategies to target ERα signaling.
Methods
Tissue culture and transfection
COS-1 monkey embryonic kidney cells, HeLa human cer-
vical cancer cells, MCF-7 cells (ATCC, Manassas, VA), and
MCF-7-LCC2 (from Robert Clarke, Ph.D., Georgetown
Univ.) were cultured in Dulbecco's minimum essential
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), and 5% penicillin/streptomycin at 37°C and
5% CO2. Ishikawa cells (provided by Steven Safe, Ph.D.,
College Station, TX) were cultured at 37°C with 5% CO2
in DMEM supplemented with 5% FBS and 1% penicillin-
streptomycin. Prior to incubation with estradiol (10-8M)
or tamoxifen (10-7M), cells were cultured in phenol red-
free DMEM or RPMI 1640 supplemented with 10% char-
coal dextran stripped FBS, and 5% penicillin/streptomy-
cin for a minimum of 24 hours. Transient transfections
were performed using Fugene 6 and in accordance with
the manufacturer instructions. To attain higher transfec-
tion efficiency, modified inactive (dead) adenovirus was
used as a transfection reagent for the in vivo labeling exper-
iments as previously described [26]. Briefly, 500 ng plas-
mid DNA and attenuated adenovirus (multiplicity of
infection, 400) were diluted in HEPES buffered saline, to
which poly-L-lysine was added to a final concentration of
12.5 ng/ml. Adenovirus/lysine solution was applied to
COS-1 cells (2 × 106) plated in serum free media. Two
hours post-transfection, DMEM containing 10% charcoal
stripped FBS was added to cells.
In vivo labeling and isolation of ERα
This laboratory previously described a detailed procedure
for in vivo [32P]H3PO4 labeling of nuclear receptors and
coactivators in mammalian cells [26,28,49]. Briefly, COS-
1 cells were cultured in 150 mm tissue culture plates (4 ×
107 cells/plate) in DMEM supplemented with charcoal
dextran stripped FBS. Medium was replaced with serum-
free medium and cells were transfected using an adenovi-
rus mediated transfection protocol (see Tissue Culture).
Prior to in vivo phosphate labeling, transfected cells were
incubated for 1.5 hours in serum free, phosphate-free
DMEM with 1% penicillin/streptomycin to deplete intra-
cellular phosphate pools. Subsequently medium was
replaced with DMEM supplemented with 1% dialyzed
FBS (to remove low molecular weight molecules such as
phosphates). Immediately after medium exchange, 4
mCi/plate of [32P]H3PO4 along with estradiol (final con-
centration of 10-8M) was added to each plate and cells
were incubated at 37°C and 5% CO2 for approximately 16
hours overnight. Following removal of medium and sev-
eral washes with PBS, cells were harvested by scraping,
cells were pelleted by centrifugation (500 × g), and pro-
tein was extracted using 4 pellet volumes (approximately
2 mls) of denaturing lysis buffer (10 mM Tris pH 8, 50
mM potassium phosphate, 50 mM sodium fluoride, 1
mM sodium vanadate, 2 mM EDTA, 2 mM EGTA, 0.4 M
sodium chloride, 5 mM α-monothioglycerol, 8 M urea,
and 1 × Pierce HALT protease inhibitor cocktail). Chro-
matin/DNA in the lysate was sheared by 8-10 passes
through a 25 gauge needle and syringe. DNA and cellular
debris was removed by ultracentrifugation at 100,000 g
for 20 minutes at 4°C. 100 μl of cleared lysate was
retained for Western blot analysis while the remaining 2
ml of cleared lysate was diluted 1:20 in PBS/0.1%BSA to
dilute the urea and prepare the lysate (total volume 40
ml) for immuno-affinity columns. ERα was purified using
an immuno-affinity column consisting of protein A con-
jugated sepharose beads (500 ml) bound by 0.5 mg
mouse monoclonal anti ERα Ab (D12, Santa Cruz).
Lysates were passed over columns two times using a peri-
staltic pump over a period of approximately 2-3 hours.
Columns were washed using 300 ml PBS/0.1%BSA/.01%
TWEEN 20 over a period of approximately 1 hour. Sepha-
rose beads were collected in PBS, ERα was eluted in 2×
Laemmli buffer and the samples were electrophoresed on
a 10% SDS PAGE gel. Following autoradiography of the
wet gel and comparison to Western blot for ERα, the cor-
responding ERα band was excised from the wet gel in
preparation for trypsin digestion (see below).
Phosphopeptide mapping
Phosphopeptide mapping of nuclear receptors and coreg-
ulators has been previously described [26,28,28,50,51].
Briefly, gel slices corresponding to ERα or ERα phospho-
mutants were excised from wet gels and incubated for 30
minutes in 50% methanol/HPLC H20 followed by brief
washes in HPLC-grade water to remove SDS and electro-
phoretic salts from the sample. Gel slices were then
digested with 10 μg trypsin in 50 mM ammonium bicar-
bonate buffer for 4 hours. 10 μg of additional trypsin was
added in 3 hour intervals for a total addition of 40 μg
trypsin. Samples were lyophilized overnight in a Speed-
Vac, and the samples were resuspended in 500 μl 50% for-
mic acid solution in preparation for HPLC separation. The
sample containing tryptic ERα peptides was loaded onto
a C-18 reversed phase column (Vydac) using a Beckman
Coulter System Gold® HPLC. A 0-45% acetonitrile gradi-
ent over 90 minutes was used to elute phosphopeptidesBMC Biochemistry 2009, 10:36 http://www.biomedcentral.com/1471-2091/10/36
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from the column. Each HPLC fraction was lyophilized,
and Cerenkov counts were measured. Based on Cerenkov
counts related to 32P peaks, HPLC fractions were com-
bined in alkaline polyacrylamide gel sample buffer (0.125
M Tris, pH 6.8, 6 M urea, 0.01% bromphenol blue pre-
pared fresh) to yield 10-13 sample groups. Individual
phosphorylated tryptic peptides were separated on 40%
alkaline polyacrylamide gels [26]. The gel was dried and
autoradiographed for 2-10 days.
Modified manual Edman degradation
A modified version of manual Edman degradation was
performed on phosphopeptides using the Millipore (Bill-
erica, MA) Sequelon-AA acrylamine disks as previously
described by this laboratory [28]47). Briefly, manual
Edman degradation was performed on phosphopeptides
isolated from either alkaline polyacrylamide gel slices or
directly from HPLC fractions. Phosphopeptides gel slices
from alkaline polyacrylamide gels were washed in 50%
methanol and the peptides extracted overnight in HPLC
water. The extracted peptides were lyophilized, Cerenkov
counts measured, and the phosphopeptides were resus-
pended in 30 μl 50% acetonitrile/0.1 TFA. For HPLC frac-
tions, the lyophilized fractions were directly resuspended
in 30 μl 50% acetonitrile/0.1 TFA.
A mylar membrane was placed on a 55°C dry bath and
peptides were spotted on Sequelon-AA disks and disks
were dried for 15 min. Peptides were coupled to mem-
branes by adding 5 μl carbimide (10 mg/ml) for 30 min-
utes at room temperature. Membranes were sequentially
washed in HPLC H2O, 100% TFA, and 100% methanol.
Phenylisothiocyanate was coupled to the N-terminus of
immobilized phosphopeptides to sensitize the peptides
to N-terminal cleavage. Disks were washed in methanol,
dried by SpeedVac, and incubated in 0.5 ml TFA for 6 min
at 55°C. The TFA solution was collected and the disks
washed with 1 ml 42.5% TFA. The fractions were com-
bined and Cerenkov counts determined as a measure of
release of the phosphoamino acid residues within the
peptide.
Phosphoamino acid analysis
Phosphoamino acid analysis has been described in detail
previously by this laboratory [28,51]. Isolation of phos-
phopeptides by HPLC and 40% alkaline acrylamide gels is
described above. Lyophilized phosphopeptides were
resuspended in 100-200 μl of 6N HCl to which 4 μg each
of purified phospho-serine, phospho-tyrosine, or phos-
pho-threonine was added. Samples were incubated 1 hour
at 110°C. Samples were dried by SpeedVac overnight,
resuspended in 15 μl of pH 1.9 buffer (2.5% formic acid,
1.8% glacial acetic acid), and spotted on 20 × 20 cm cel-
lulose thin layer chromatography plates. Samples were
electrophoresed in the first dimension for 20 min at 1500
V (toward negatively charged electrode) using the Hunter
HTLE 7000 electrophoresis system (CBS Scientific Del
Mar, CA). After drying, plates were then subjected to sec-
ond dimension electrophoresis. Plates were equilibrated
in pH 3.5 buffer (5% glacial acetic acid, 0.5% pyridine in
dH2O) and a second round of electrophoresis was per-
formed in pH 3.5 buffer for 15 minutes at 1300V with
plates rotated 90°. Plates were dried for 1 hour. Ninhy-
drin (5 μg/ml acetone, Pierce, Rockford, IL) was applied
to the plates using an atomizer (General Glassblowing,
Inc.) and plates incubated at 80°C for 1-5 minutes to vis-
ualize phosphoamino acid standards. Standards were
then outlined and radiolabeled sample phosphopeptides
visualized by autoradiography. Comparison to migration
of phosphoamino acid standards was used to determine
the identity of phosphorylated amino acid residues.
Generation of ERα phospho-mutants
ERα S46A, S47A S46/S47A, S282A, S294A, and S559A
phospho-mutant expression plasmids were constructed
using the either the Quick-change XL™ (Stratagene) or
GeneEditor™ (Promega) site directed mutagenesis kit in
accordance with the manufacturer's instructions. Briefly,
mutagenesis primers encoding serine to alanine muta-
tions for S47, S282, S294, and S559 were designed in
accordance with Stratagene primer design software, and
were as follows:
S46A-Fwd:5'-.GGTGTACCTGGACGCCAG-
CAAGCCCGCC
S46A-Rev:5'-.GGCGGGCTTGCTGGCGTCCAGGTACACC
S46/47A-Fwd:5'-.GGTGTACCTGGACGCCG-
CAAAGCCCGCC
Rev:5'-.GGCGGGCTTTGCGGCGTCCAGGTACACC
S47A- Fwd: 5'-GTGTACCTGGACAGCGCAAAGCCCGCCGT-
GTAC-3'
Rev: 5'-GTACACGGCGGGCTTTGCGCTGTCCAGGTA-
CAC-3'
S282- 5'-Fwd: GGGTGAAGTGGGGGCAGCTGGAGACAT-
GAGA-3'
Rev:5'-TCTCATGTCTCCAGCTGCCCCCACTTCACCC-3'
S294-Fwd: 5'-ACCTTTGGCCAGCCCCGCTCATGAT-3'
Rev: 5'-ATCATGAGCGGGGCCGGCCAAAGGT
S559 Fwd: 5'-GGAGGGGCAGCTGCTGAGGAGACG-3'
Rev:5'-CGTCTCCTCCACAGCTGCCCCTCC-3'BMC Biochemistry 2009, 10:36 http://www.biomedcentral.com/1471-2091/10/36
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For S47A and S282A, PCR reactions were assembled using
pCR3.1wt ERα (template DNA), 125 ng each fwd and rev
mutagenesis primers, 1 μl Stratagene dNTP mix, and 2.5 u
Pfu turbo DNA polymerase. PCR conditions were as fol-
lows: 95° for 50 seconds, 60°C for 60 seconds, and 68°C
for 5 minutes for 18 cycles followed by final extension for
10 minutes at 68°C. Methylated template DNA strands
were digested using DPN1 and the reaction transformed
into XL10 gold E. coli cells. Clones were grown on 100 μg/
ml ampicillin LB agar plates and 5 selected clones were
amplified in 5 ml liquid cultures with LB/amp medium.
Mini-plasmid preps were performed using alkaline lysis
and the isolated plasmid DNA sequenced to determine
the incorporation of the desired serine to alanine muta-
tions.
For S294A and S559A, alkaline denatured pCR3.1wt ERα
(template DNA) was hybridized to mutagenic (145 ng)
and antibiotic resistance oligonucleotides (2.9 ng each)
and in the presence of 1× annealing buffer in 20 μl a reac-
tion volume. The reactions were heated to 75°C, for 5
minutes, and allowed to cool to 37°C utilizing a thermal
cycler. Mutant strands were synthesized in reaction utiliz-
ing 10 u T4 polymerase and 3 u DNA ligase with 1× syn-
thesis buffer in a final volume of 30 ul, and were incubate
at 37°C for 90 minutes. Plasmid DNA was subsequently
transformed into BMH 71-18 mutS E. coli, cultured in the
presence of GeneEditor™ antibiotic selection mix over-
night, and plasmid minipreps performed. A second round
of plasmid minipreps were performed using DH5α com-
petent E. coli prior to usage in experiments. Plasmid DNA
was subsequently sequenced to confirm serine to alanine
mutations.
ERα phospho-specific antibodies
Generation of phospho-specific ERα antibodies has been
previously described [29]. Briefly, rabbit polyclonal anti-
bodies to phosphorylated peptides corresponding to
phosphorylated S47, S282, S294 and S559 were generated
by Bethyl Laboratories (Montgomery, Texas). Immuno-
genic phosphopeptides were as follows:
pS47 [CEVYLDS(pS)KPAVY],
pS282, [CGRGEVG(pS)AGDMR] pS294, [CRAAN-
LWP(pS)PLMIK] and pS559(CTSRGGA(pS)VEET).
Rabbits were injected subcutaneously with immunogen/
adjuvant mixture that was re-administered at day 14 and
day 44. Animal sera were collected on days 54 and 60, and
subsequently at two week intervals. Antibody titers were
measured by ELISA and phospho-specific antibodies were
affinity purified with the corresponding antigen. Anti-
body specificity was validated as previously described
[29]. Briefly, 106 COS-1 cells were transiently transfected
with 500 ng ERα or ERα phospho-mutant expression plas-
mids with Fugene 6 in accordance with the manufacturer's
instructions. Specificity of ERα phospho-antibodies was
determined by Western immunoblotting as described
below. Antibodies were further validated by in vitro λ
phosphatase treatment [29]. 400 ng of purified baculovi-
rus expressed ERα was incubated with 200 ng λ phos-
phatase in 1× phosphatase buffer for 30 minutes in a total
of 200 μl at 30°C. Reactions were terminated by boiling
in a final concentration of 1× Laemmli buffer for 5 min-
utes. The samples were then electrophoresed and immu-
noblotted using phospho-specific antibodies or total ERα
antibodies as described below.
Immunoprecipitation/Western blot analysis
Western blot analysis for estrogen receptor has been
described previously [4]. Cells were cultured in phenol-
red free growth medium supplemented with 10% char-
coal stripped FBS for 24 hours prior to incubation of cells
with estradiol. Cells were incubated with vehicle or 10-8
estradiol for 30 minutes. Total protein was extracted in
high salt buffer (10 mM Tris-HCl, pH 8; 0.4 M NaCl; 2
mM EDTA; 2 mM EGTA; 50 mM potassium phosphate; 50
mM sodium fluoride; 10 mM-mercaptoethanol; 0.1% Tri-
ton X-100; 0.2% protease inhibitor cocktail; and 0.1%
phenylmethylsulfonyl fluoride) and samples denatured
with Laemmli buffer with boiling for 3 minutes. Proteins
were fractionated by SDS-PAGE on 10% polyacrylamide
gels and electrophoretically transferred to nitrocellulose
membranes for 2 hours. Blots were blocked in 5% BSA
TBS-T (10 mM Tris, pH 8; 150 mM NaCl; 0.1% Tween-
20), and incubated with α-ERα and α-pERα primary anti-
bodies (1:1000) overnight at 4°C. Following washes in
TBS-T, secondary detection was performed using LI-COR
(Lincoln, NB) near-Infrared fluorescent labeled goat α-
rabbit/α-mouse secondary antibodies (1:10000) and
membranes were read using the LI-COR Odyssey infrared
imaging system (Lincoln, NB). Primary antibodies used
for Western Blot analysis included α-ERα (B2051, Bethyl
Labs, (Montgomery, TX) or D-12, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), or custom α-phospho-ERα gener-
ated at Bethyl Laboratories (Montgomery, TX) (see ERα
phospho-specific antibodies).
For immunoprecipitation experiments, 107  Ishikawa,
MCF7, or MCF-7-LCC2, cells were lysed in IP/Western
buffer (200 mM Tris pH 8.0, 250 mM NaCl, 0.1 mM
EDTA, 0.5% NP-40, 0.2% protease inhibitor cocktail; and
0.1% phenylmethylsulfonyl fluoride). 5 μg of α-ERα,
pS282, pS294, or pS559 antibody and 10 μl protein A
conjugated magnetic beads were added to 500 μl (2-3 mg
total protein) cell lysate, incubated with turning at 4°C for
3 hours. Beads were collected using magnetic tube racks,
and the beads washed 3 times with IP lysis buffer. ERα was
eluted in 2× Laemmli with boiling for 3 minutes. Western
blots were performed as described above.BMC Biochemistry 2009, 10:36 http://www.biomedcentral.com/1471-2091/10/36
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Luciferase reporter assay
HeLa cervical cancer cells were plated at 1 × 105 cells/well
in 24 well plates in phenol red free DMEM with 10% char-
coal-stripped FBS. Cells were transfected with 100 ng
ERE2-TK-Luc reporter and 200 ng wild type ERα (wt ERα)
or ERα mutant expression plasmids (S47A, S282A, S294A,
or S559A) using Fugene 6 as described under tissue cul-
ture and transfections). After 24 hours, each set of trans-
fectants were incubated with vehicle or estradiol (10-8M)
for 18 hours. Cells were lysed with 200 μl 1× reporter lysis
buffer. 100 μl was loaded and luciferase activity measured
using Promega™ luciferase reporter assay system. ERα/
ERα mutant expression was determined to be equivalent
per unit protein, and luciferase reporter assay normalized
to total protein. Each treatment group was plated in quad-
ruplicate and the experiment repeated a minimum of
three times.
Quantitative real-time RT-PCR
Real time RT-PCR to measure pS2 and GAPDH mRNA
expression was performed using the RT-PCR primers and
cycling parameters described previously [4]. Briefly, HeLa
cells (2 × 106) cultured in phenol red free DMEM supple-
mented with 10% charcoal stripped FBS in 10 cm dishes
were transfected with 500 ng of ERα or ERα mutant
expression plasmid. 24 hours post transfection, transfect-
ants were incubated with vehicle or estradiol (10-8M) for
3 hours. RNA was isolated using Trizol™ reagent according
to manufacturer protocol. Single step RT-PCR was per-
formed using iScript™ one step RT-PCR kit, BioRad™ with
500 ng RNA in 25 μl reactions. pS2 expression was nor-
malized to GAPDH expression and expression estimated
using the comparative CT method outlined in the Gene-
Amp 5700 users manual and as previously described by
this laboratory (7). Experiments were repeated a mini-
mum of three times.
Statistical Analysis
In RT-PCR and reporter gene expression experiments, sig-
nificance differences (P ≤ 0.05) were determined using
analysis of variance (ANOVA) and Fisher's LSD post hoc
analysis.
In vitro kinase assay
In vitro kinase assays were performed as previously
described [29,42,43,49,52,53]. Briefly, purified baculovi-
rus expressed ERα (300 ng), (Invitrogen, Carlsbad, CA)
was incubated with 100 ng recombinant human protein
kinase CK2α (New England Biolabs™ Ipswich, MA) iso-
lated from E. coli in CK2 reaction buffer (20 mM Tris-HCl
50 mM KCl 10 mM MgCl2 pH 7.5) supplemented with
200 μM ATP for 30 minutes at 25°C. Control reactions
excluding ERα or CK2α were also assembled to assess the
specificity of experimental reactions. Reactions were
stopped by addition of 2× Laemmli buffer and phosphor-
ylation was determined by Western blot analysis for total
ERα and pS282 or pS559 antibodies as described above.
In order to assess specificity of phosphorylation, Western
blot analysis for the non-CK2 ERα phosphorylation site
S118 was performed as described above. Experiments
were performed a minimum of three times.
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